Editor's Note: At OBR we have created an editorial board of renown thought leaders in different cancer disease areas. The role of our editorial board is to provide valuable insights through editorial commentary accompanying our daily news. We call it virtual access. By providing our insights into the daily news, you will have access into how these thought leading oncologists interpret the oncology news and events we carry in OBR daily. We hope that our editorial boards's insights will bring great value to the oncology community.
Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Very interesting …
Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director, Clinical Research
Director Clinical Oncology Research, RWJ-B Health System
Once again, despite our hopes, and the imagination of the public, that a magic-bullet immunotherapy …
Director WVU Cancer Institute
Director of Cancer Signature Program
Laurence S. and Jean J. DeLynn Chair of Oncology
This is a very interesting study that opens the door to prospective investigation of a randomized tr…
Executive Director
Community Oncology Alliance
This is yet another mandatory experiment on cancer patient care that is terrible medicine and uncons…
National Health Policy Expert
C-VICER: CVS Embraces ICER
We have reached a v…
Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine
Grover C. Bagby Chair of Prostate Cancer Research
OHSU Knight Cancer Institute Deputy Director, OHSU Knight Cancer Institute, School of Medicine
Chief Medical Officer, CEDAR, OHSU Knight Cancer Institute, School of Medicine
This study provides an important aggregate assessment of how men weigh survival and adverse effects …
Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA; CEO, Global Resource for Advancing Cancer Education (GRACE)
While it's nice to have a new approval, this is also a setting in which the IMpower150 regimen offer…
President, W-Squared Group
This piece is a great example of a pathway program in process. Clinical pathways are not meant to b…
Managing Director and Senior Biotechnology Analyst
I am excited to be joining the editorial board on OBR; I have been a fan of the publication since it…
Chief Medical Officer and Founder, N-of-One
No comments to show!
Professor and Director, Division of Hematology Oncology
Department of Medicine,Cedars-Sinai Medical Center
Associate Director for Academic Program Development
Samuel Oschin Comprehensive Cancer Institute
Professor of Medicine and Urology, Emeritus
David Geffen School of Medicine at UCLA
This long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …
FACP FACPE FASCO
President, Minnesota Oncology
In contrast, chemotherapy initiation in the outpatient setting is being continually delayed due to p…
CEO
Tennessee Oncology
I found this article both fascinating and enlightening. I had not thought of "burnout" in terms of …
Vice President
Integrated Community Oncology Network
Former Community Representative
ASCO Board of Directors
OK so I went into this with an negative attitude but actually to give the devil his due they actual…
Florida Cancer Specialists
President and Managing Partner
Like the data…
Ronald H. Bloom Chair in Cancer Therapeutics
Professor and Chair, Department of Radiation Oncology
Interim Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
It's very challenging to run clinical trials when patients are randomized to very different treatmen…
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.
